Inspire was incorporated in October 1993 and began operations in March 1995. We completed an Initial Public Offering of common stock in August 2000. Inspire's common stock is traded on the Nasdaq Global Market under the ticker symbol "ISPH." We are located in Durham, North Carolina, adjacent to Research Triangle Park.
Inspire was founded based on technology licensed from the University of North Carolina (UNC) at Chapel Hill. Research conducted by a team at UNC's Cystic Fibrosis Research Center led to the discovery that uridine triphosphate (UTP), which is a naturally occurring compound in the body, is capable of increasing airway surface hydration and improving mucociliary clearance through activation of the P2Y receptor.
Inspire scientists, working with UNC researchers, immersed themselves in the emerging field of P2Y receptors, and were soon recognized as leaders in the discovery and synthesis of nucleotides that activate the P2Y2 receptor. Our scientists made and patented many discoveries relating to P2Y2 receptors, their agonists and their potential importance in the treatment of diseases involving deficiencies in the body's natural mechanisms for protecting mucosal surfaces within the lungs and on the eyes. Based on this technology platform, we have discovered and are developing product candidates for treating dry eye (PROLACRIATM, the proposed U.S. tradename for diquafosol tetrasodium ophthalmic solution 2%) and cystic fibrosis (denufosol tetrasodium).
In 2004, Inspire licensed several patents for use in developing and commercializing new treatments for glaucoma from the Wisconsin Alumni Research Foundation (WARF). We have developed this research into a unique technology platform and are currently developing two molecules (INS115644 and INS117548) for the treatment of glaucoma.
We have generated a substantial patent portfolio of U.S. patents from our P2Y2 and other research areas.
In late 2003, Inspire built a specialized sales force of 64 representatives dedicated to calling on ophthalmologists, optometrists and allergists in the United States. Our sales force has since grown to approximately 90 representatives that currently promote AZASITE® (azithromycin ophthalmic solution) 1% and also co-promote ELESTAT® (epinastine HCl ophthalmic solution) 0.05% through an agreement with Allergan, Inc.
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
DURHAM, N.C., Sep 01, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the appoin...
Inspire Announces Amendment to Ophthalmic Collaboration
DURHAM, N.C., Aug 25, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has ent...
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer
- Experienced Pulmonologist and Cystic Fibrosis Drug Development Expert Joins Inspire -
DURHAM, N.C., Aug 13, 2010 ...
Inspire Announces Webcast of Presentation at Bank of America Merrill Lynch Specialty Pharmaceuticals Conference
DURHAM, N.C., Aug 05, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adria...
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 5/24/2010
